From the Department of Cardiology, Patras University Hospital, Patras, Rion 26500, Greece.
Lipids Health Dis. 2013 Nov 9;12:170. doi: 10.1186/1476-511X-12-170.
Previous studies have demonstrated gaps in achievement of low-density lipoprotein-cholesterol (LDL-C) goals among patients at very high cardiovascular risk. We aimed to investigate lipid treatment patterns, rates and predictors of lipid targets attainment, in such outpatients in an urban area of Greece.
This was a prospective observational study, conducted in 19 outpatient clinics of Western Greece. We recruited patients with established cardiovascular disease (CVD) and/or diabetes mellitus (DM), previously (at least 3 months before baseline assessment) untreated with any lipid lowering medication. Lipid profile assessment was performed at baseline (prior to lipid-lowering treatment initiation) and at follow-up. Lipid lowering treatment choice was at physicians' discretion and was kept constant until follow-up.
We recruited 712 patients with a mean age 61.4 ± 10.4 years, 68.0% males, 43.0% with DM, 64.7% with prior coronary artery disease-CAD. In total, 237/712 (33.3%) of prescribed regimens were of high or very high LDL-C lowering efficacy and out of them 113/237 (47.7%) comprised a combination of statin and ezetimibe. At follow-up the primary target of LDL-C < 70 mg/dL (1.8 mmol/L) was achieved in 71(10.0%) patients. The secondary target of non-HDL-C < 100 mg/dL (2.6 mmol/L) in the subgroup of patients with DM or increased triglycerides levels (>150 mg/dl or 1.7 mmol/L) was achieved in 45(11.6%) of patients. In multivariate logistic regression analysis (AUC = 0.71, 95% CIs 0.65-0.77, p < 0.001) male gender, smoking, baseline LDL-C and very high potency LDL-C lowering regimen emerged as independent predictors of LDL-C goal attainment (OR = 1.88, 95% CIs 1.03-3.44, p = 0.04, OR = 0.57, 95% CIs 0.33-0.96, p = 0.04, OR = 0.98, 95% CIs 0.98-0.99, p < 0.001 and OR = 2.21, 95% CIs 1.15-4.24, p = 0.02 respectively).
First-line management of dyslipidemia among very-high cardiovascular risk outpatients in Western Greece is unsatisfactory, with the majority of treated individuals failing to attain the LDL-C and non-HDL-C targets. This finding points out the need for intensification of statin treatment in such patients.
先前的研究表明,极高心血管风险患者的低密度脂蛋白胆固醇(LDL-C)目标达标情况存在差距。我们旨在研究在希腊西部城区的此类门诊患者中,血脂治疗模式、血脂目标达标率及其预测因素。
这是一项前瞻性观察性研究,在希腊西部的 19 家门诊诊所进行。我们招募了患有已确诊心血管疾病(CVD)和/或糖尿病(DM)且至少在基线评估前 3 个月未接受任何降脂药物治疗的患者。在基线(开始降脂治疗前)和随访时进行血脂谱评估。降脂治疗方案的选择由医生决定,并在随访期间保持不变。
我们共招募了 712 名平均年龄为 61.4±10.4 岁的患者,其中 68.0%为男性,43.0%患有 DM,64.7%患有既往冠状动脉疾病(CAD)。在总共 712 名患者中,237 名(33.3%)接受的治疗方案具有较高或非常高的 LDL-C 降低效果,其中 113 名(47.7%)包含他汀类药物和依折麦布的联合治疗。在随访时,71 名(10.0%)患者达到 LDL-C<70mg/dL(1.8mmol/L)的主要目标。在患有 DM 或甘油三酯水平升高(>150mg/dl 或 1.7mmol/L)的患者亚组中,非高密度脂蛋白胆固醇<100mg/dL(2.6mmol/L)的次要目标达到 45 名(11.6%)。在多变量逻辑回归分析(AUC=0.71,95%置信区间 0.65-0.77,p<0.001)中,男性、吸烟、基线 LDL-C 和非常高的 LDL-C 降低效果的降脂方案被确定为 LDL-C 目标达标率的独立预测因素(OR=1.88,95%置信区间 1.03-3.44,p=0.04;OR=0.57,95%置信区间 0.33-0.96,p=0.04;OR=0.98,95%置信区间 0.98-0.99,p<0.001;OR=2.21,95%置信区间 1.15-4.24,p=0.02)。
在希腊西部城区,极高心血管风险门诊患者的血脂异常一线管理并不令人满意,大多数接受治疗的个体未能达到 LDL-C 和非高密度脂蛋白胆固醇的目标。这一发现表明,此类患者需要加强他汀类药物的治疗。